Derivation of embryonic stem cells and embryo-derived cells

• US 10,072,243 B2
• Filed: 03/02/2017
• Issued: 09/11/2018
• Est. Priority Date: 11/04/2004
• Status: Active Grant

• Current Assignee: Astellas Institute for Regenerative Medicine (Astellas Pharma Incorporated)
• Original Assignee: Astellas Institute for Regenerative Medicine (Astellas Pharma Incorporated)
• Inventors: Chung, Young Gie, Lanza, Robert P., Klimanskaya, Irina V.
• Primary Examiner(s): Noble, Marcia Stephens
• Application Number:
  US15/448,571
• Publication Number:
  US 20170240857A1
• Time in Patent Office: 558 Days
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/873 Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/998 Proteins not provided for elsewhere
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0603 Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies
• CPC Class Codes: C12N 5/0604 Whole embryos; Culture medium therefor
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

Abstract

This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.

Claims

1. A method of producing human embryonic stem (ES) cells, comprising:

(a) culturing a blastomere obtained from a human embryo in medium containing less than 5 mM glucose to generate a cluster of two or more blastomeres;

(b) directly or indirectly contacting the cultured cluster of two or more blastomeres with embryonic or fetal cells; and

(c) culturing the cluster of two or more blastomeres of (b) to produce ES cells.

2. A method of producing human embryonic stem (ES) cells, comprising:

(a) culturing a blastomere obtained from a human embryo in medium containing less than 5 mM glucose to generate a cluster of two or more blastomeres;

(b) directly or indirectly contacting the cultured cluster of two or more blastomeres with medium sufficient to promote the growth and survival of the cultured cluster of two or more blastomeres that is supplemented with ACTH; and

(c) culturing the cluster of two or more blastomeres of (b) to produce ES cells.

3. The method of claim 2, wherein (a) comprises culturing a blastomere obtained from a human embryo in medium containing less than 5 mM glucose and having a osmolarity of less than 310 mOsm to generate a cluster of two or more blastomeres.

4. The method of claim 2, wherein the medium sufficient to promote the growth and survival of the cultured cluster of two or more blastomeres is medium conditioned with embryonic or fetal cells.